Literature DB >> 3678967

Effect of polymer coating on faecal recovery of ingested 5-amino salicylic acid in patients with ulcerative colitis.

H A Mardini1, D C Lindsay, C M Deighton, C O Record.   

Abstract

It has been suggested that polymer coating might retard jejunal absorption of 5-amino salicylic acid (5-ASA) and thus promote delivery to its colonic site of action. Twenty three patients with active (nine), or quiescent (14) ulcerative colitis were given either uncoated or coated 5-ASA (Asacol) 400 mg qds for one to three weeks, after which they ingested five 1.5 ml dialysis membrane sachets which were recovered from the stool in the next 72 hours. After one week of treatment the concentration of 5-ASA in the faecal dialysate, urine, and fasting plasma in those receiving the coated and uncoated preparations were respectively: 25.4 +/- 5.1 compared with 1.2 +/- 0.4 mmol/l (p less than 0.001); 0.34 +/- 0.21 compared with 0.70 +/- 0.29 mmol/24h (NS) and 11.1 +/- 4.2 compared with 0.07 +/- 0.03 mumol/l (p less than 0.02). Faecal excretion of the drug appeared to be greater in patients with active colitis than in those with quiescent disease. Thus coating with pH dependent methacrylic acid copolymer B is a very effective method of promoting delivery of 5-ASA to the colon, stool dialysate concentrations being 20 fold more than those in controls. Increased trough plasma concentrations in the polymer coating group probably reflect delayed intestinal absorption but no evidence of plasma accumulation after 21 days of therapy was found.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3678967      PMCID: PMC1433240          DOI: 10.1136/gut.28.9.1084

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  17 in total

1.  Distribution studies of salicylazosulfapyridine and its metabolites.

Authors:  M A Peppercorn; P Goldman
Journal:  Gastroenterology       Date:  1973-02       Impact factor: 22.682

2.  Exacerbation of diarrhoea and pain in patients treated with 5-aminosalicylic acid for ulcerative colitis.

Authors:  C A Austin; P A Cann; T H Jones; C D Holdsworth
Journal:  Lancet       Date:  1984-04-21       Impact factor: 79.321

3.  Maintenance of remission in ulcerative colitis with 5-amino salicylic acid in high doses by mouth.

Authors:  M J Dew; A D Harries; N Evans; B K Evans; J Rhodes
Journal:  Br Med J (Clin Res Ed)       Date:  1983-07-02

4.  Treatment of ulcerative colitis with oral 5-aminosalicyclic acid in patients unable to take sulphasalazine.

Authors:  M J Dew; A D Harries; B K Evans; J Rhodes
Journal:  Lancet       Date:  1983-10-01       Impact factor: 79.321

5.  Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid.

Authors:  M J Dew; P Hughes; A D Harries; G Williams; B K Evans; J Rhodes
Journal:  Br Med J (Clin Res Ed)       Date:  1982-10-09

6.  Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas.

Authors:  M Campieri; G A Lanfranchi; G Bazzocchi; C Brignola; F Sarti; G Franzin; A Battocchia; G Labo; P R Dal Monte
Journal:  Lancet       Date:  1981-08-08       Impact factor: 79.321

7.  Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease.

Authors:  U Klotz; K Maier; C Fischer; K Heinkel
Journal:  N Engl J Med       Date:  1980-12-25       Impact factor: 91.245

8.  Colonic release of 5-amino salicylic acid from an oral preparation in active ulcerative colitis.

Authors:  M J Dew; R E Ryder; N Evans; B K Evans; J Rhodes
Journal:  Br J Clin Pharmacol       Date:  1983-08       Impact factor: 4.335

9.  The determination of oxalate in haemodialysate and plasma: a means to detect and study 'hyperoxaluria' in haemodialysed patients.

Authors:  B G Wolthers; S Meijer; T Tepper; M Hayer; H Elzinga
Journal:  Clin Sci (Lond)       Date:  1986-07       Impact factor: 6.124

10.  Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine.

Authors:  P A van Hees; J H Bakker; J H van Tongeren
Journal:  Gut       Date:  1980-07       Impact factor: 23.059

View more
  12 in total

Review 1.  Hydrogen sulphide: a bacterial toxin in ulcerative colitis?

Authors:  M C Pitcher; J H Cummings
Journal:  Gut       Date:  1996-07       Impact factor: 23.059

Review 2.  Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs.

Authors:  S G Nugent; D Kumar; D S Rampton; D F Evans
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

Review 3.  Medical treatment of ulcerative colitis: scoring the advances.

Authors:  C J Hawkey; A B Hawthorne
Journal:  Gut       Date:  1988-10       Impact factor: 23.059

4.  Modulation of colonic hydrogen sulfide production by diet and mesalazine utilizing a novel gas-profiling technology.

Authors:  Chu K Yao; Asaf Rotbart; Jian Z Ou; Kourosh Kalantar-Zadeh; Jane G Muir; Peter R Gibson
Journal:  Gut Microbes       Date:  2018-05-09

5.  Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis.

Authors:  G Frieri; R Giacomelli; M Pimpo; G Palumbo; A Passacantando; G Pantaleoni; R Caprilli
Journal:  Gut       Date:  2000-09       Impact factor: 23.059

Review 6.  Inflammatory bowel disease.

Authors:  G M Van Rosendaal
Journal:  CMAJ       Date:  1989-07-15       Impact factor: 8.262

7.  The contribution of sulphate reducing bacteria and 5-aminosalicylic acid to faecal sulphide in patients with ulcerative colitis.

Authors:  M C Pitcher; E R Beatty; J H Cummings
Journal:  Gut       Date:  2000-01       Impact factor: 23.059

8.  Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study.

Authors:  Hiroaki Ito; Mitsuo Iida; Takayuki Matsumoto; Yasuo Suzuki; Hidetaka Sasaki; Toyomitsu Yoshida; Yuichi Takano; Toshifumi Hibi
Journal:  Inflamm Bowel Dis       Date:  2010-09       Impact factor: 5.325

Review 9.  Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1989-10       Impact factor: 9.546

10.  Direct comparison of two different mesalamine formulations for the maintenance of remission in patients with ulcerative colitis: a double-blind, randomized study.

Authors:  Hiroaki Ito; Mitsuo Iida; Takayuki Matsumoto; Yasuo Suzuki; Yoshiyuki Aida; Toyomitsu Yoshida; Yuichi Takano; Toshifumi Hibi
Journal:  Inflamm Bowel Dis       Date:  2010-09       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.